Literature DB >> 29506079

The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.

Britta Weigelt1, Rui Bi1,2, Rahul Kumar1, Pedro Blecua3, Diana L Mandelker1, Felipe C Geyer1, Fresia Pareja1, Paul A James4, Fergus J Couch5, Diana M Eccles6, Fiona Blows7, Paul Pharoah7, Anqi Li1,2, Pier Selenica1, Raymond S Lim1, Gowtham Jayakumaran1, Nic Waddell8, Ronglai Shen9, Larry Norton10, Hannah Y Wen1, Simon N Powell3, Nadeem Riaz3, Mark E Robson10, Jorge S Reis-Filho1, Georgia Chenevix-Trench8.   

Abstract

Pathogenic germline variants in ataxia-telangiectasia mutated (ATM), a gene that plays a role in DNA damage response and cell cycle checkpoints, confer an increased breast cancer (BC) risk. Here, we investigated the phenotypic characteristics and landscape of somatic genetic alterations in 24 BCs from ATM germline mutation carriers by whole-exome and targeted sequencing. ATM-associated BCs were consistently hormone receptor positive and largely displayed minimal immune infiltrate. Although 79.2% of these tumors exhibited loss of heterozygosity of the ATM wild-type allele, none displayed high activity of mutational signature 3 associated with defective homologous recombination DNA (HRD) repair. No TP53 mutations were found in the ATM-associated BCs. Analysis of an independent data set confirmed that germline ATM variants and TP53 somatic mutations are mutually exclusive. Our findings indicate that ATM-associated BCs often harbor bi-allelic inactivation of ATM, are phenotypically distinct from BRCA1/2-associated BCs, lack HRD-related mutational signatures, and that TP53 and ATM genetic alterations are likely epistatic.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29506079      PMCID: PMC6136925          DOI: 10.1093/jnci/djy028

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  20 in total

Review 1.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.

Authors:  Yosef Shiloh; Yael Ziv
Journal:  Nat Rev Mol Cell Biol       Date:  2013-03-13       Impact factor: 94.444

2.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.

Authors:  A R Pettitt; P D Sherrington; G Stewart; J C Cawley; A M Taylor; T Stankovic
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

3.  Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.

Authors:  Emma Nolan; Peter Savas; Antonia N Policheni; Phillip K Darcy; François Vaillant; Christopher P Mintoff; Sathana Dushyanthen; Mariam Mansour; Jia-Min B Pang; Stephen B Fox; Charles M Perou; Jane E Visvader; Daniel H D Gray; Sherene Loi; Geoffrey J Lindeman
Journal:  Sci Transl Med       Date:  2017-06-07       Impact factor: 17.956

4.  Molecular and genetic properties of tumors associated with local immune cytolytic activity.

Authors:  Michael S Rooney; Sachet A Shukla; Catherine J Wu; Gad Getz; Nir Hacohen
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

5.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

6.  Dominant negative ATM mutations in breast cancer families.

Authors:  Georgia Chenevix-Trench; Amanda B Spurdle; Magtouf Gatei; Helena Kelly; Anna Marsh; Xiaoqing Chen; Karen Donn; Margaret Cummings; Dale Nyholt; Mark A Jenkins; Clare Scott; Gulietta M Pupo; Thilo Dörk; Regina Bendix; Judy Kirk; Katherine Tucker; Margaret R E McCredie; John L Hopper; Joseph Sambrook; Graham J Mann; Kum Kum Khanna
Journal:  J Natl Cancer Inst       Date:  2002-02-06       Impact factor: 13.506

7.  Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.

Authors:  Maarten P G Massink; Irsan E Kooi; Saskia E van Mil; Ekaterina S Jordanova; Najim Ameziane; Josephine C Dorsman; Daphne M van Beek; J Patrick van der Voorn; Daoud Sie; Bauke Ylstra; Carolien H M van Deurzen; John W Martens; Marcel Smid; Anieta M Sieuwerts; Vanja de Weerd; John A Foekens; Ans M W van den Ouweland; Ewald van Dyk; Petra M Nederlof; Quinten Waisfisz; Hanne Meijers-Heijboer
Journal:  Mol Oncol       Date:  2015-01-13       Impact factor: 6.603

8.  BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.

Authors:  Kara N Maxwell; Bradley Wubbenhorst; Brandon M Wenz; Daniel De Sloover; John Pluta; Lyndsey Emery; Amanda Barrett; Adam A Kraya; Ioannis N Anastopoulos; Shun Yu; Yuchao Jiang; Hao Chen; Nancy R Zhang; Nicole Hackman; Kurt D'Andrea; Robert Daber; Jennifer J D Morrissette; Nandita Mitra; Michael Feldman; Susan M Domchek; Katherine L Nathanson
Journal:  Nat Commun       Date:  2017-08-22       Impact factor: 14.919

9.  CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer.

Authors:  Mark D M Leiserson; Hsin-Ta Wu; Fabio Vandin; Benjamin J Raphael
Journal:  Genome Biol       Date:  2015-08-08       Impact factor: 13.583

10.  Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes.

Authors:  Nadeem Riaz; Pedro Blecua; Raymond S Lim; Ronglai Shen; Daniel S Higginson; Nils Weinhold; Larry Norton; Britta Weigelt; Simon N Powell; Jorge S Reis-Filho
Journal:  Nat Commun       Date:  2017-10-11       Impact factor: 14.919

View more
  43 in total

1.  Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.

Authors:  Na Li; Simone McInerny; Magnus Zethoven; Dane Cheasley; Belle W X Lim; Simone M Rowley; Lisa Devereux; Norah Grewal; Somayeh Ahmadloo; David Byrne; Jue Er Amanda Lee; Jason Li; Stephen B Fox; Thomas John; Yoland Antill; Kylie L Gorringe; Paul A James; Ian G Campbell
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

2.  A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability.

Authors:  Katerina D Fagan-Solis; Dennis A Simpson; Rashmi J Kumar; Luciano G Martelotto; Lisle E Mose; Naim U Rashid; Alice Y Ho; Simon N Powell; Y Hannah Wen; Joel S Parker; Jorge S Reis-Filho; John H J Petrini; Gaorav P Gupta
Journal:  Cell Rep       Date:  2020-02-04       Impact factor: 9.423

3.  Molecular profiling and molecular classification of endometrioid ovarian carcinomas.

Authors:  Paulina Cybulska; Arnaud Da Cruz Paula; Jill Tseng; Mario M Leitao; Ali Bashashati; David G Huntsman; Tayyebeh M Nazeran; Carol Aghajanian; Nadeem R Abu-Rustum; Deborah F DeLair; Sohrab P Shah; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2019-07-21       Impact factor: 5.482

4.  Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.

Authors:  Kenneth L Pitter; Dana L Casey; Yue C Lu; Margaret Hannum; Zhigang Zhang; Xinmao Song; Isabella Pecorari; Biko McMillan; Jennifer Ma; Robert M Samstein; Isaac X Pei; Atif J Khan; Lior Z Braunstein; Luc G T Morris; Christopher A Barker; Andreas Rimner; Kaled M Alektiar; Paul B Romesser; Christopher H Crane; Joachim Yahalom; Michael J Zelefsky; Howard I Scher; Jonine L Bernstein; Diana L Mandelker; Britta Weigelt; Jorge S Reis-Filho; Nancy Y Lee; Simon N Powell; Timothy A Chan; Nadeem Riaz; Jeremy Setton
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

5.  Molecular Characterization of a Rare Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation in a 24 Year Old.

Authors:  Nicholas Olson; Rodrigo Gularte-Mérida; Pier Selenica; Arnaud Da Cruz Paula; Barbara Alemar; Britta Weigelt; Joel Lefferts; Konstantinos Linos
Journal:  Int J Surg Pathol       Date:  2019-12-04       Impact factor: 1.271

6.  Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.

Authors:  Catherine H Marshall; Alexandra O Sokolova; Andrea L McNatty; Heather H Cheng; Mario A Eisenberger; Alan H Bryce; Michael T Schweizer; Emmanuel S Antonarakis
Journal:  Eur Urol       Date:  2019-02-21       Impact factor: 20.096

7.  Massively parallel sequencing analysis of benign melanocytic naevi.

Authors:  John R Lozada; Felipe C Geyer; Pier Selenica; David Brown; Barbara Alemar; Taha Merghoub; Michael F Berger; Klaus J Busam; Allan C Halpern; Britta Weigelt; Jorge S Reis-Filho; Travis J Hollmann
Journal:  Histopathology       Date:  2019-05-24       Impact factor: 5.087

8.  BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer.

Authors:  Ying L Liu; Pier Selenica; Qin Zhou; Alexia Iasonos; Margaret Callahan; Noah Z Feit; Julia Boland; Ignacio Vazquez-Garcia; Diana Mandelker; Ahmet Zehir; Robert A Burger; Daniel J Powell; Claire Friedman; Karen Cadoo; Rachel Grisham; Jason A Konner; Roisin E O'Cearbhaill; Carol Aghajanian; Jorge S Reis-Filho; Britta Weigelt; Dmitriy Zamarin
Journal:  JCO Precis Oncol       Date:  2020-06-16

9.  Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma.

Authors:  Fresia Pareja; David N Brown; Ju Youn Lee; Arnaud Da Cruz Paula; Pier Selenica; Rui Bi; Felipe C Geyer; Andrea Gazzo; Edaise M da Silva; Mahsa Vahdatinia; Anthe A Stylianou; Lorenzo Ferrando; Hannah Y Wen; James B Hicks; Britta Weigelt; Jorge S Reis-Filho
Journal:  Clin Cancer Res       Date:  2020-03-27       Impact factor: 12.531

Review 10.  ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.

Authors:  Samantha A Armstrong; Christopher W Schultz; Ariana Azimi-Sadjadi; Jonathan R Brody; Michael J Pishvaian
Journal:  Mol Cancer Ther       Date:  2019-11       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.